

Attorney Docket No.: **PENN-0065**  
Inventors: **Wolfe and Fraser**  
Serial No.: **08/393,066**  
Filing Date: **February 23, 1995**  
Page 2

In the Claims:

*objection* 1. (amended) A method of delivering a selected DNA sequence to the central nervous system of a mammal comprising administering a neurotropic viral vector [capable of infecting] which infects the central nervous system of a mammal, said vector containing a selected DNA sequence, said sequence being operatively linked to a selected promoter.

REMARKS

Claims 1-9 are pending in this application. Claims 1-9 have been rejected. Claim 1 has been amended. Reconsideration is respectfully requested in light of this amendment and the following remarks.

**I. Objection to Specification and Rejection of Claims 1-9 under 35 U.S.C. §112, first paragraph**

The objection to the specification and rejection of claims 1-9 under 35 U.S.C. §112, first paragraph, have been maintained, as the Examiner suggests that it is not apparent from the disclosure that the method would sufficiently deliver a gene to the central nervous system. As acknowledged by the Examiner, Applicants have shown that biologically active  $\beta$ -glucuronidase can be expressed when the DNA sequence for an HSV vector is administered by corneal abrasion.